![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Osi Pharmaceuticals Inc. (MM) | NASDAQ:OSIP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 57.49 | 0 | 01:00:00 |
FORM 3
|
Washington, D.C. 20549 |
OMB APPROVAL
OMB Number: 3235-0104 Expires: February 28, 2011 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person * Epstein David M. |
2. Date of Event Requiring Statement (MM/DD/YYYY)
|
3. Issuer Name and Ticker or Trading Symbol OSI PHARMACEUTICALS INC [OSIP] |
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below) Sr. VP and CSO, Oncology / |
|
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially Owned |
|||
1.Title of Security
(Instr. 4) |
2. Amount of Securities Beneficially Owned
(Instr. 4) |
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) |
4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Common Stock | 14246 (1) | D |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||
1. Title of Derivate Security
(Instr. 4) |
2. Date Exercisable and Expiration Date
(MM/DD/YYYY) |
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) |
4. Conversion or Exercise Price of Derivative Security |
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) |
6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Stock Option (Right to Buy) | 5/1/2007 (2) | 4/30/2013 | Common Stock | 7084 (6) | $26.21 | D | |
Stock Option (Right to Buy) | 12/13/2007 (3) | 12/12/2013 | Common Stock | 4000 (6) | $37.74 | D | |
Stock Option (Right to Buy) | 12/12/2008 (3) | 12/11/2014 | Common Stock | 17500 (6) | $47.29 | D | |
Stock Option (Right to Buy) | 12/15/2010 (4) | 12/14/2019 | Common Stock | 11250 (6) | $35.40 | D | |
Stock Option (Right to Buy) | 12/16/2011 (5) | 12/15/2015 | Common Stock | 22500 (6) | $33.62 | D |
Explanation of Responses: | |
( 1) | Consists of (i) 1,937 shares of OSI Common Stock, (ii) 2,500 shares of Restricted Stock, which vest on May 1, 2010, and (iii) 9,809 Restricted Stock Units, which vest over a period of 4 years from their respective dates of grant. Dr. Epstein will receive one share of OSI Common Stock upon the vesting of each Restricted Stock Unit. |
( 2) | 25% of the option became exerciseable one year after the date of grant and the remainder will vest ratably on a monthly basis over the succeeding 36 months. |
( 3) | 25% of the option became exerciseable one year after the date of grant and the remainder will vest ratably on an annual basis over the succeeding 3 years. |
( 4) | 25% of the option will become exerciseable one year after the date of grant and the remainder will vest ratably on an annual basis over the succeeding 3 years. |
( 5) | One third of the stock option grant will become exercisable on each of the third, fourth and fifth anniversaries of the grant date. |
( 6) | Includes only options with the same termination date. |
Remarks:
Exhibit List: Exhibit 24--Power of Attorney |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
Epstein David M.
C/O OSI PHARMACEUTICALS, INC. 41 PINELAWN ROAD MELVILLE, NY 11747 |
|
|
Sr. VP and CSO, Oncology |
|
Signatures
|
||
/s/ Pierre Legault, attorney-in-fact for Dr. Epstein | 4/9/2010 | |
** Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Osi Pharmaceuticals Chart |
1 Month Osi Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions